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Aims: To compare overnight closed-loop and sensor-augmented pump therapy in patients with type 1 diabetes by combining data collected during
free-living unsupervised randomized crossover home studies.
Methods: A total of 40 participants with type 1 diabetes, of whom 24 were adults [mean± standard deviation (s.d.) age 43± 12 years and glycated
haemoglobin (HbA1c) 8.0± 0.9%] and 16 were adolescents (mean± s.d. age 15.6± 3.6 years and HbA1c 8.1± 0.8%), underwent two periods of
sensor-augmented pump therapy in the home setting, in combination with or without an overnight closed-loop insulin delivery system that uses a
model predictive control algorithm to direct insulin delivery. The order of the two interventions was random; each period lasted 4weeks in adults and
3weeks in adolescents. The primary outcome was time during which sensor glucose readings were in the target range of 3.9–8.0mmol/l.
Results: The proportion of time when sensor glucose was in the target range (3.9–8.0mmol/l) overnight (between 24:00 and 08:00 hours) was 18.5%
greater during closed-loop insulin delivery than during sensor-augmented therapy (p< 0.001). Closed-loop therapy significantly reduced mean overnight
glucose levels by 0.9mmol/l (p< 0.001), with no difference in glycaemic variability, as measured by the standard deviation of sensor glucose. Time spent
above the target range was reduced (p= 0.001), as was time spent in hypoglycaemia (<3.9mmol/l; p= 0.014) during closed-loop therapy. Lower mean
overnight glucose levels during closed-loop therapy were brought about by increased overnight insulin delivery (p< 0.001) without changes to the total
daily delivery (p= 0.84).
Conclusion: Overnight closed-loop insulin therapy at home in adults and adolescents with type 1 diabetes is feasible, showing improvements in glucose
control and reducing the risk of nocturnal hypoglycaemia.
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Introduction
Intensive insulin therapy reduces the risks of macro- and
microvascular complications in type 1 diabetes [1,2] but is
limited by hypoglycaemia, a key barrier to achieving tight
glycaemic control [3]. Nocturnal hypoglycaemia remains a
significant concern because of its morbidity and link with
sudden unexpected death in type 1 diabetes [4,5]. Achieving
persistent euglycaemia safely overnight may help reduce the
risk and burden to patients, carers and their families.
The closed-loop system delivers insulin in a continually
glucose-responsive manner by combining subcutaneous con-
tinuous glucose monitoring and subcutaneous insulin pump
delivery [6]. This novel approach differs from conventional
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insulin pump therapy in its use of a control algorithm, which
automatically directs insulin delivery based on real-time sensor
glucose levels. Randomized controlled trials in research facil-
ity settings in adults and children with type 1 diabetes have
reported improvements in overnight glucose control whilst
reducing the risk of nocturnal hypoglycaemia [7–9] and tran-
sitional studies, characterized by close monitoring in diabetes
camp and hotel settings, have paved the way for closed-loop
system use in out-of-hospital settings [10,11].
Unsupervised home studies constitute the ultimate ‘testbed’,
as investigations under free-living conditions provide unequiv-
ocal assessment of closed-loop performance and its usability in
the target environment. To increase our understanding of the
benefits of unsupervised overnight closed-loop therapy across
a wide age range, we pooled data from two recent home stud-
ies in adolescents and adults with type 1 diabetes [12,13]. We
were particularly interested to ascertain if closed-loop therapy
reduced time spent in hypoglycaemia, somethingwhich the two
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individual studies failed to detect because of their limited sam-
ple size and low background rates of nocturnal hypoglycaemia.
Participants and Methods
Participants and Experimental Protocol
Data were pooled from adult and adolescence overnight
closed-loop studies performed in unsupervised settings in the
patient’s home [12,13]. Between 1 July 2012 and 23 December
2013, adults aged ≥18 years were enrolled from diabetes clinics
at Addenbrooke’s Hospital, Cambridge, Sheffield Teaching
Hospitals, Sheffield and Kings College Hospital, London, and
adolescents aged 12–18 years were enrolled from Paediatric
Diabetes Clinics at Addenbrooke’s Hospital, Cambridge and
University College Hospital, London. Inclusion criteria were:
type 1 diabetes (World Health Organization criteria); >1 year
from diagnosis or confirmed C-peptide-negative; insulin
pump therapy for ≥3months; four or more capillary glucose
measurements per day; and glycated haemoglobin (HbA1c)
level ≤10% (86mmol/mol). Exclusion criteria included: estab-
lished nephropathy; neuropathy or proliferative retinopathy;
total daily insulin dose ≥2.0U/kg; regular use of continuous
glucose monitoring <1month before enrolment; severe visual
or hearing impairment; and pregnancy or breast feeding.
After a 2–4-week run-in phase, participants applied insulin
pump therapy with real-time continuous glucose monitoring
at home on two periods with or without overnight closed-loop
therapy. Each period lasted 4 (adults) or 3 (adolescents) weeks.
Identical insulin pump and real-time continuous glucose mon-
itoring devices were used during the two study periods, which
were separated by a 3–4-week washout period, during which
participants used their own pump and discontinued continu-
ous glucose monitoring.
Signed informed consent was obtained from all participants
aged ≥16 years, and from parents or guardians of participants
aged <16 years (assent was obtained from minors). Both study
protocols were approved by the East of England Central Cam-
bridge Ethics Committee.The trials were registered under Clin-
ical Trials numbers NCT01440140 and NCT01221467.
Randomization and Blinding
The order of the two study periods was random and was
determined after the run-in phase using computer-generated
permuted block randomization. During the run-in phase, the
continuous glucose monitor receiver was modified to mask the
recorded sensor glucose concentrations. Downloaded sensor
glucose readings were used to optimize the study insulin
pump therapy before randomization. Participants had access
to sensor glucose readings after the end of the run-in phase.
Study Procedures
Blood samples for plasma glucose and C-peptide measure-
ments were taken after enrolment. Participants were trained
on the features of the study insulin pump (Dana R Diabecare;
Sooil, Seoul, South Korea) and continuous glucose moni-
toring (FreeStyle Navigator; Abbott Diabetes Care, Alameda,
CA, USA). After the run-in period, compliance was demon-
strated by the use the continuous glucose monitor for at least
14 (adults) and 8 days (adolescents). Participants used the
rapid-acting insulin analogue normally used in their usual clin-
ical care and the built-in bolus wizard of the insulin pump dur-
ing both interventions to calculate insulin boluses at mealtimes
andwhen administering correction boluses. Usual basal insulin
delivery settings were also applied on the study pump.
The continuous glucose monitoring device was calibrated
according to the manufacturer’s instructions. The sensor glu-
cose threshold alarm for hypoglycaemia was initially set at
3.5mmol/l and could be modified by participants. During the
closed-loop period, overnight insulin delivery was automati-
cally directed by a closed-loop model predictive control algo-
rithm [14].
The adult participants spent the first closed-loop night in
the local clinical research facility and received training in
the use of the closed-loop system. In the adolescence cohort,
closed-loop training was provided to the participants and par-
ents at home during the first closed-loop night. Training lasted
for 60–90min and covered initiation and discontinuation of the
closed-loop system and problem troubleshooting. Participants
were instructed to start the system at home after their evening
meal, and to discontinue it before breakfast the next morning.
Participants were trained to check capillary glucose versus sen-
sor glucose values (calibration check) before evening meals; if
sensor glucose was greater than capillary glucose by>3mmol/l,
the continuous glucose monitor was recalibrated and the cali-
bration check was repeated before starting the closed-loop sys-
tem. These instructions reduced the risk of sensor error and
the calibration check approach, expected to occur infrequently
once every 3–4weeks, was effective when assessed by computer
modelling [15].
No further supervision took place over the following nights
and participants used the system fully unsupervised. Partici-
pants were not restricted in dietary intake or daily activities. A
24-h telephone support service assisted participants in clinical
or technical issues that arose during the study. All participants
were given troubleshooting literature and user manuals for
all study devices. Standard local hypoglycaemia and hyper-
glycaemia treatment guidelines were followed. The data from
the study insulin pumps and continuous glucose monitoring
devices were downloaded by the research team at the end
of study periods. In addition, during closed-loop therapy,
encrypted data from the closed-loop system was emailed by
the participants to the study team once a week.
Closed-Loop System
TheFlorence automated closed-loop system comprised amodel
predictive control algorithm residing on a hand-held computer
linked by cable to the continuous glucose monitoring receiver
[14]. Every 12min, the treat-to-target algorithm calculated a
new insulin infusion rate, which was automatically set on the
study pump via wireless communication.
At setup, the research team entered participants’ weight and
total daily insulin dose on the first night during which the
closed-loop system was used. Data for carbohydrate intake, as
entered by participants into the insulin pump built-in bolus
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wizard, were automatically downloaded to the hand-held com-
puter during the use of the closed-loop system. Insulin delivery
history, includingmanually instructed insulin boluses, was also
automatically downloaded.
Laboratory Assays
Baseline random C-peptide levels were measured using a
chemiluminescence immunoassay (Liaison XL; DiaSorin
Deutschland GmbH, Dietzenbach, Germany; interassay coeffi-
cients of variation 5.6% at 563 pmol/l, 4.5% at 2529 pmol/l and
5.8% at 5449 pmol/l). HbA1c was measured centrally with ion
exchange high-performance liquid chromatography (G8HPLC
Analyzer; Tosoh Bioscience, South San Francisco, CA, USA;
interassay coefficients of variation 1.3% at 31.2mmol/mol and
0.8% at 80.5mmol/mol).
Outcomes
The primary efficacy outcome was the time spent in the target
glucose range (3.9–8.0mmol/l) between 24:00 and 08:00 hours,
as recorded by continuous glucose monitoring. Secondary out-
comes included mean glucose concentration, time spent at
glucose levels <3.9mmol/l (hypoglycaemia) and >8.0mmol/l
(hyperglycaemia), and insulin delivery. Overnight glucose vari-
ability was assessed by the standard deviation and the coeffi-
cient of variation of continuous glucose monitoring levels. We
assessed hypoglycaemia burden by calculating the glucose sen-
sor area under the curve<3.5mmol/l.We calculated secondary
outcomes from 24:00 to 08:00 hours and over 24 h.
Statistics
Analyses were carried out on an intention-to-treat basis.
Normally distributed data were compared using the paired
t-test and non-normally distributed data using the Wilcoxon
signed-rank test. Results are presented as mean [standard
deviation (s.d.)] or median [interquartile range (IQR)], unless
stated otherwise. p values <0.05 were taken to indicate sta-
tistical significance. Outcomes were calculated using GStat
software (version 2.0, University of Cambridge) and statistical
analyses were conducted using spss (version 21).
Results
Baseline Characteristics
A total of 24 adults and 16 adolescents completed both study
periods. Baseline characteristics are shown in Table 1.
Primary and Secondary Outcomes Overnight
The primary endpoint, the proportion of time when overnight
sensor glucose levels were in the target range, was significantly
increased by a mean of 18.4% [95% confidence interval (CI)
13.5–23.4%; p< 0.001] during closed-loop therapy (Table 2).
Closed-loop therapy significantly reducedmean overnight sen-
sor glucose by 0.9mmol/l (95% CI 0.4–1.3mmol/l; p< 0.001),
as well as the proportion of time when sensor glucose val-
ues were in hyperglycaemia (>8.0mmol/l; mean 15.9%, 95%
Table 1. Baseline characteristics.
Adults (n= 24)* Adolescents (n= 16)*
Age, years 43± 12 15.6± 2.1
Gender: male/female 13/11 10/6
Body mass index, kg/m2 26.0± 3.5 22.4± 3.7
HbA1c
% 8.1± 0.8 8.0± 0.9
mmol/mol 64.9± 8.9 63.9± 9.4
Duration of diabetes, years 29± 11 7.2± 4.3
Duration on pump, years 6.3± 4.4 3.0± 2.3
Total daily insulin, U/kg/day 0.5± 0.1 0.8± 0.2
HbA1c, glycated haemoglobin. Data are mean± standard deviation unless
otherwise indicated.
*All with C-peptide levels lower than 33 pmol/l.
CI 10.7–21.0%; p< 0.001) and hypoglycaemia (<3.9mmol/l;
median 0.9%, 95% CI 0.2–2.2; p= 0.014; Table 2, Figure 1).
There was no significant difference in the burden of hypogly-
caemia as measured by the area under the curve when sensor
glucose levels were <3.5mmol/l (p= 0.15).
Glucose variability overnight measured as standard devia-
tion was similar during the two interventions. The mean± s.d.
coefficient of variation of overnight glucose within each night
was higher during closed-loop than during sensor-augmented
pump therapy (25.2± 3.5% vs. 22.8± 5.0%; p= 0.023; Table 2).
Conversely, the between-nights coefficient of variation of
overnight glucose was significantly reduced by closed-loop
therapy (24.8± 6.9% vs. 29.1± 6.9%; p= 0.002).
Exploratory per-protocol analysis, considering nights
when the closed-loop system was turned on for at least 6 h
(closed-loop period) or sensor data were available for at
least 6 h (control period), showed that closed-loop therapy
increased the proportion of time overnight spent in target
by 20.7% (95% CI 15.7–25.6%; p< 0.001; Table 3). This was
achieved by reducing mean glucose levels by 1.0mmol/l (95%
CI 0.5–1.4mmol/l; p< 0.001) as well as reducing time spent
below target overnight by a median of 3.2% (95% CI 0.8–5.0%;
p= 0.005).
Secondary Outcomes From Midnight to Midnight
Endpoints calculated over 24 h showed that the overnight
closed-loop system significantly increased the proportion of
time spent within a wider target range of 3.9–10.0mmol/l
by a mean of 4.7% (95% CI 2.0–7.5%; p= 0.001; Table 4).
Overnight closed-loop therapy reduced the overallmean sensor
glucose level by a mean of 0.5mmol/l (95% CI 0.1–1.0mmol/l;
p= 0.016). This was achieved by significantly reducing both
proportion of time spent over 24 h with glucose above the tar-
get by a mean of 7.0% (95% CI 3.6–10.3%; p< 0.001) and by
reducing the proportion of time spent in hypoglycaemia by a
median of 1.6% (95% CI 0.4–2.8%; p= 0.015).
Insulin Requirements and Utility of the Closed-Loop System
The closed-loop system delivered 17% more insulin overnight
(p< 0.001; Table 5).The total daily insulin deliveredwas similar
during the two interventions (p= 0.84). Adult and adolescent
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Table 2. Intention-to-treat comparison of glucose outcomes from 24:00 to 08:00 hours during overnight closed-loop therapy and the control period in the
home setting over 3–4weeks.
Closed-loop period (n= 40) Control period (n= 40) p
Mean± s.d. glucose, mmol/l 7.9± 0.9 8.7± 1.4 <0.001
Mean± s.d. within-night standard deviation of glucose, mmol/l 2.0± 0.3 1.9± 0.3 0.47
Mean± s.d. within-night coefficient of variation of glucose, % 25.2± 3.5 22.8± 5.0 0.023
Mean± s.d. between-nights coefficient of variation of glucose, % 24.8± 6.9 29.1± 6.9 0.002
Mean± s.d. proportion of time spent at glucose level, %
3.9–8.0mmol/l* 59.2± 11.5 40.7± 13.4 <0.001
3.9–10.0mmol/l 77.4± 8.6 61.8± 13.3 <0.001
>8.0mmol/l 37.9± 12.4 53.8± 17.0 0.001
Median (IQR) proportion of time spent at glucose level, %
>16.7mmol/l 0.66 (0.0, 2.3) 1.3 (0.0, 2.8) 0.15
<3.9mmol/l 1.9 (0.7, 3.5) 2.9 (1.0, 6.4) 0.014
<3.5mmol/l 0.7 (0.3, 2.0) 1.1 (0.21, 3.9) 0.098
<2.8mmol/l 0.2 (0.0, 0.6) 0.2 (0.0, 1.3) 0.29
Median (IQR) AUCday <3.5mmol/l, mmol/l×min 4.7 (1.2, 16.9) 6.4 (0.4, 33.8) 0.15
Mean± s.d. glucose at 24:00 hours, mmol/l 9.1± 1.3 9.0± 1.8 0.39
Mean± s.d. glucose at 08:00 hours, mmol/l 7.7± 0.92 9.0± 1.4 <0.001
AUCday, Glucose area under curve below 3.5 mmol/l per day; IQR, interquartile range; s.d., standard deviation.
*Primary endpoint.
Figure 1. Individual values of mean glucose levels and proportion of
time spent at low glucose levels (<3.9mmol/l) in the whole cohort.
Line plots show individual values of mean overnight glucose during the
intention-to-treat analysis. The diameter of each circle is proportional to
the percentage of time that each participant spent with a low glucose value
<3.9mmol/l.
participants used closed-loop therapy of their own volition
for 87% (856 nights) of the whole study duration (Table S1).
Closed-loop therapy was used for a median of 9 h at home
each night; the median closed-loop therapy start time was
22:37 hours and the stop time was 07:30 hours. The causes and
frequency of unintentional closed-loop interruptions are listed
in Table S1.
Adverse Events
There were two episodes of hyperglycaemia associated with
ketosis (blood ketones>1.5mmol/l) during the control period,
and one occasion during the closed-loop period. Two episodes
of severe hypoglycaemia occurred during the closed-loop
period in two adults who each had a history of hypoglycaemia
unawareness, and both events happened at a time when the
closed-loop system was not operational. Post hoc analysis
showed that closed-loop operation was interrupted 1 h before
these two episodes occurred because of disrupted wireless
connectivity with the insulin pump. Before this interruption,
insulin delivery had already been suspended by the algorithm
because of predicted low glucose concentrations. In 1 par-
ticipant, the event was probably compounded by increased
physical activity during the day. User error, that is, overde-
livery of insulin whilst changing infusion set overnight, was
deemed to be the likely contributory cause in the second
participant. Both participants recovered fully with no clinical
sequelae.
Discussion
This pooled analysis adds to the observations in two previous
studies that adults and adolescents with type 1 diabetes are able
to use closed-loop therapy safely and effectively overnight at
home over an extended period, without the need for remote
monitoring or close supervision. The combined evaluation of
the two aforementioned studies [12,13] provides greater power
and allows comprehensive assessment of closed-loop bene-
fits across a wide age range. A clinically significant reduction
in overnight glucose was observed accompanied by reduced
time spent in a hypoglycaemic state. Such combined effect
has not been documented with any other means of inten-
sified conventional insulin delivery in type 1 diabetes. Glu-
cose variability between nights was reduced by closed-loop
therapy in the study, whilst increased variability within each
night is explained by similarly elevated sensor glucose levels at
midnight during both interventions, accompanied by consis-
tent lower morning glucose at 08:00 hours during closed-loop
therapy.
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Table 3. Comparison of glucose outcomes from 24:00 to 08:00 hours, with at least 6 h of closed-loop operation (intervention group) and 6 h of sensor data
(control group).
Closed-loop group (n= 40) Control group (n= 40) p
Number of nights 786 881
Mean± s.d. glucose, mmol/l 7.8± 0.96 8.7± 1.4 <0.001
Mean± s.d. proportion of time spent at glucose level 3.9–8.0mmol/l, % 61.3± 12.5 40.6± 13.4 <0.001
Median (IQR) proportion of time spent at glucose level <3.9mmol/l, % 1.1 (0.58, 2.9) 2.9 (0.8, 5.8) 0.005
Median (IQR) AUCday <3.5mmol/l, mmol/l×min 2.5 (0.34, 10.1) 6.2 (0.21, 33.8) 0.09
Mean± s.d. lucose at 24:00 hours, mmol/l 9.0± 1.3 9.0± 1.9 0.69
Mean± s.d. lucose at 08:00 hours, mmol/l 7.7± 1.1 9.0± 1.3 <0.001
AUCday, Glucose area under curve below 3.5 mmol/l per day; IQR, interquartile range; s.d., standard deviation.
Table 4. Comparison of 24-h glucose outcomes during overnight closed-loop therapy and the control period in the home setting over 3–4weeks.
Closed-loop period (n= 40) Control period (n= 40) p
Mean± s.d. glucose, mmol/l 8.6± 1.2 9.1± 1.4 0.016
Mean± s.d. proportion of time spent at glucose level, %
3.9–10.0mmol/l 63.6± 9.9 58.8± 10.5 0.001
>10.0mmol/l 29.5± 10.5 36.5± 13.3 <0.001
Median (IQR) proportion of time spent at glucose level <3.9mmol/l, % 1.8 (0.91, 3.2) 2.7 (1.3, 5.7) 0.015
Median (IQR) AUCday < 3.5mmol/l, mmol/l×min 5.2 (2.0, 12.1) 6.9 (2.4, 29.5) 0.078
AUCday, Glucose area under curve below 3.5 mmol/l per day; IQR, interquartile range; s.d., standard deviation.
Glucose concentrations remained lower over 24 h, sug-
gesting there are extended benefits of improved overnight
glucose control even when closed-loop therapy is stopped.
Furthermore, fasting morning glucose levels were 14% lower
after overnight closed-loop therapy. As a result, participants
were able to administer fewer insulin boluses and corrections
during the day. This may explain the similar total daily insulin
dosage for both study periods, in spite of the 17% increase in
overnight insulin delivery during closed-loop.
Real-time continuous glucose monitoring is associated with
a mean HbA1c reduction of 0.5% (5.5mmol/mol) [16–18]
and an unchanged risk of nocturnal hypoglycaemia [19]. Ado-
lescents appear to benefit less, owing to a reduction in time
when the glucose sensor was used [20]. Frequent insulin dos-
ing and infusion rate adjustments tomatch glycaemia levels and
day-to-day variations in insulin sensitivity represent significant
challenges and burden to subjects, their families and health-
care professionals. A more recent technological approach, the
threshold-suspend insulin pump, interrupts insulin delivery
for up to 2 h when at a low glucose threshold. Its application
reduces nocturnal frequency and duration of hypoglycaemia
[21,22], but is unable to step up insulin delivery during episodes
of elevated glucose levels and does not alter overall glucose con-
trol [22].
Our closed-loop algorithm accounts for variations in insulin
requirements, finely modulating insulin delivery based on
real-time sensor glucose levels and maintaining more consis-
tent glucose levels overnight. Other closed-loop systems have
been studied in outpatient and home settings, albeit for a
shorter duration or under remote monitoring and supervision
[11,23–25]. Compared with standard pump therapy, subjects
on a bihormonal closed-loop system in an outpatient setting
for 5 days had lower mean glucose levels and less frequent
hypoglycaemic episodes [26]. Overnight closed-loop therapy
in children and adolescents at a diabetes camp over 5–6 days
showed significant reductions in times spent at various hypo-
glycaemia glucose levels, but no significant difference in the
intention-to-treat analysis was observed for median percent-
age of time in the glucose range of 3.9–8.3mmol/l [26]. A sin-
gle night closed-loop intervention at a diabetes camp showed
a reduction in the frequency and duration of hypoglycaemia
<3.5 and 3.3mmol/l, with a reduction of overnight median
glucose by 0.8mmol/l [11]. The same group reported sig-
nificant reductions in time spent with sensor glucose levels
<3.9mmol/l and an increased percentage of time spent in the
target range (3.9–7.8mmol/l) during a 6-week single-centre
overnight closed-loop home study [27]. In contrast to the
present multicentre study, however, a remote monitoring sys-
tem was used and thus the research team was immediately
alerted of technical failures aswell as hypo- and hyperglycaemia
events during overnight closed-loop therapy.
The strength of the present study is the rigour of the
intention-to-treat analysis and duration of closed-loop use. Its
distinguishing feature is free-living unsupervised use in home
settings. Other studies performed in out-of-hospital settings
were either shorter or were performed under remote moni-
toring, whereby investigators could intervene clinically during
episodes of significant hypo- or hyperglycaemia, and could
manage technical faults during the study on behalf of partic-
ipants. Participants in the present study were not restricted in
their activities or dietary habits, and used closed-loop therapy at
home of their own volition; thus, experimentally, these studies
are the first to report on the utility and efficacy of closed-loop
therapy under real-life day-to-day conditions without partici-
pants being directly monitored or supervised. The randomized
crossover design of the present study allowed the participants to
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Table 5. Insulin delivery overnight (24:00–08:00 hours) and over 24 h.
Closed-loop period, n= 40 Control period, n= 40
Median (IQR) Median (IQR) p
Overnight insulin delivery, U 7.0 (5.4, 9.3) 6.0 (4.7, 7.4) <0.001
Total daily insulin delivery, U 40.3 (32.9, 52.6) 39.4 (32.8, 55.8) 0.84
s.d. of overnight insulin delivery, U 0.6 (0.5, 0.8) 0.1 (0.07, 0.2) <0.001
IQR, interquartile range; s.d., standard deviation.
act as their own control.We acknowledge that the findings were
limited by usability of the system. Closed-loop therapy inter-
ruptions occurred on average once every five nights. More than
60% of interruptions were attributable to disruptions to the
pump wireless connectivity or loss of sensor glucose availabil-
ity. Participants’ positive and negative experiences and quality
of life may thus have been affected by various aspects of system
utility [28]. The experience and utilisation rate of 87% may be
further enhanced by improvements in device connectivity.
In conclusion, unsupervised use of overnight closed-loop
therapy in adults and adolescents with type 1 diabetes is feasi-
ble. Benefits include improved overnight glucose control with
reduction in time spent in a hypoglycaemic state. Longer-term
studies are warranted using devices with more reliable
connectivity.
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Additional Supporting Information may be found in the online
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Table S1.Utility and failure analysis of closed-loop operation.
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